Developments in Securities Fraud Class Actions Against U.S. Life Sciences Companies
Categories: Hi-Tech
Plaintiffs, in the US, filed a total of 43 securities class action lawsuits against life sciences companies in 2022, which represented almost one in four securities class action lawsuits.
A Dechert survey, for any Israeli life sciences companies with a US presence, identifying various trends relating to the origin of such suits, including issues stemming from misrepresentations regarding efficacy and safety, sufficiency of FDA applications, and unlawful conduct.